A simple clinical scoring system using ferritin, fasting insulin, and type IV collagen 7S for predicting steatohepatitis in nonalcoholic fatty liver disease (original) (raw)

Abstract

Background

Liver histology is the gold standard for the diagnosis of nonalcoholic steatohepatitis (NASH). Noninvasive, simple, reproducible, and reliable biomarkers are greatly needed to differentiate NASH from nonalcoholic fatty liver disease (NAFLD).

Methods

To construct a scoring system for predicting NASH, 177 Japanese patients with biopsy-proven NAFLD were enrolled. To validate the scoring system, 442 biopsy-proven NAFLD patients from eight hepatology centers in Japan were also enrolled.

Results

In the estimation group, 98 (55%) patients had NASH. Serum ferritin [≥200 ng/ml (female) or ≥300 ng/ml (male)], fasting insulin (≥10 μU/ml), and type IV collagen 7S (≥5.0 ng/ml) were selected as independent variables associated with NASH, by multilogistic regression analysis. These three variables were combined in a weighted sum [serum ferritin ≥200 ng/ml (female) or ≥300 ng/ml (male) = 1 point, fasting insulin ≥10 μU/ml = 1 point, and type IV collagen 7S ≥5.0 ng/ml = 2 points] to form an easily calculated composite score for predicting NASH, called the NAFIC score. The area under the receiver operating characteristic (AUROC) curve for predicting NASH was 0.851 in the estimation group and 0.782 in the validation group. The NAFIC AUROC was the greatest among several previously established scoring systems for detecting NASH, but also for predicting severe fibrosis.

Conclusions

NAFIC score can predict NASH in Japanese NAFLD patients with sufficient accuracy and simplicity to be considered for clinical use.

Access this article

Log in via an institution

Subscribe and save

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Ludwig J, Viggiano TR, McGill DB, Ott BJ. Non-alcoholic steatohepatitis. Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc. 1980;55:434–8.
    CAS PubMed Google Scholar
  2. Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver diseases: a spectrum of clinical and pathological severity. Gastroenterology. 1999;116:1413–9.
    Article CAS PubMed Google Scholar
  3. Rafiq N, Bai C, Fang Y, Srishord M, McCullough A, Gramlich T, et al. Long-term follow-up of patients with nonalcoholic fatty liver. Clin Gastroenterol Hepatol. 2009;7:234–8.
    Article PubMed Google Scholar
  4. Saibara T. Nonalcoholic steatohepatitis in Asia-Oceania. Hepatol Res. 2005;33:64–7.
    Article PubMed Google Scholar
  5. Hamaguchi M, Kojima T, Takeda N, Nakagawa T, Taniguchi H, Fujii K, et al. The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. Ann Intern Med. 2005;143:722–8.
    CAS PubMed Google Scholar
  6. Vuppalanchi R, Chalasani N. Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: selected practical issues in their evaluation and management. Hepatology. 2009;49:306–17.
    Article PubMed Google Scholar
  7. Wieckowska A, McCullough AJ, Feldstein AE. Noninvasive diagnosis and monitoring of nonalcoholic steatohepatitis: present and future. Hepatology. 2007;46:582–9.
    Article CAS PubMed Google Scholar
  8. Ratziu V, Charlotte F, Heurtier A, Gombert S, Giral P, Bruckert E, et al. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology. 2005;128:1898–906.
    Article PubMed Google Scholar
  9. Merriman RB, Ferrell LD, Patti MG, Weston SR, Pabst MS, Aouizerat BE, et al. Correlation of paired liver biopsies in morbidly obese patients with suspected nonalcoholic fatty liver disease. Hepatology. 2006;44:874–80.
    Article PubMed Google Scholar
  10. Pagadala M, Zein CO, McCullough AJ. Predictors and advanced fibrosis in non-alcoholic fatty liver disease. Clin Liver Dis. 2009;13:591–606.
    Article PubMed Google Scholar
  11. Sumida Y, Nakashima T, Yoh T, Furutani M, Hirohama A, Kakisaka Y, et al. Serum thioredoxin levels as a predictor of steatohepatitis in patients with nonalcoholic liver disease. J Hepatol. 2003;38:32–8.
    Article CAS PubMed Google Scholar
  12. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41:1313–21.
    Article PubMed Google Scholar
  13. Japanese Society for the Study of Obesity. New criteria of obesity (in Japanese). J Jpn Soc Study Obes. 2000;6:18–28.
    Google Scholar
  14. American Diabetes Association. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care. 1997;20:1183–97.
    Google Scholar
  15. Dixon JB, Bhathal PS, O’Brien PE. Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology. 2001;121:91–100.
    Article CAS PubMed Google Scholar
  16. Katz A, Nambi SS, Mather K, Baron AD, Follmann DA, Sullivan G, et al. Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab. 2000;85:2402–10.
    Article CAS PubMed Google Scholar
  17. Palekar NA, Naus R, Larson SP, Ward J, Harrison SA. Clinical model for distinguishing nonalcoholic steatohepatitis from simple steatosis in patients with nonalcoholic fatty liver disease. Liver Int. 2006;26:151–6.
    Article PubMed Google Scholar
  18. Gholam PM, Flancbaum L, Machan JT, Charney DA, Kotler DP. Nonalcoholic fatty liver disease in severely obese subjects. Am J Gastroenterol. 2007;102:399–408.
    Article CAS PubMed Google Scholar
  19. Ratziu V, Giral P, Charlotte F, Bruckert E, Thibault V, Theodorou I, et al. Liver fibrosis in overweight patients. Gastroenterology. 1999;118:1117–23.
    Article Google Scholar
  20. Harrison SM, Oliver D, Arnold HLM, Gogia SM, Neuschwander-Tetri BAM. Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease. Gut. 2008;57:1441–7.
    Article CAS PubMed Google Scholar
  21. Angulo P, Hui JM, Marchesini G, Bugianesi E, George J, Farrell GC, et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology. 2007;45:846–54.
    Article CAS PubMed Google Scholar
  22. Miyaaki H, Ichikawa T, Nakao K, Yatsuhashi H, Furukawa R, Ohba K, et al. Clinicopathological study of nonalcoholic fatty liver disease in Japan: the risk factors for fibrosis. Liver Int. 2008;28:519–24.
    Article PubMed Google Scholar
  23. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Non-alcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol. 1999;94:2467–74.
    Article CAS PubMed Google Scholar
  24. Bonkovsky HL, Jawaid Q, Tortorelli K, LeClair P, Cobb J, Lambrecht RW, et al. Non-alcoholic steatohepatitis and iron: increased prevalence of mutations of the HFE gene in non-alcoholic steatohepatitis. J Hepatol. 1999;31:421–9.
    Article CAS PubMed Google Scholar
  25. Bugianesi E, Manzini P, D’Antico S, Vanni E, Longo F, Leone N, et al. Relative contribution of iron burden, HFE mutations, and insulin resistance to fibrosis in nonalcoholic fatty liver. Hepatology. 2004;39:179–87.
    Article CAS PubMed Google Scholar
  26. Yoneda M, Nozaki Y, Endo H, Mawatari H, Iida H, Fujita K, et al. Serum ferritin is a clinical biomarker in Japanese patients with nonalcoholic steatohepatitis (NASH) independent of HFE gene mutation. Dig Dis Sci. 2010;55:808–14.
    Article CAS PubMed Google Scholar
  27. Chitturi S, Weltman M, Farrell GC, McDonald D, Kench J, Liddle C, et al. HFE mutations, hepatic iron, and fibrosis: ethnic-specific association of NASH and C282Y but not with fibrotic severity. Hepatology. 2002;36:142–9.
    Article CAS PubMed Google Scholar
  28. Sumida Y, Yoshikawa T, Okanoue T. Role of hepatic iron in non-alcoholic steatohepatitis. Hepatol Res. 2009;39:213–22.
    Article CAS PubMed Google Scholar
  29. Jehn M, Clark JM, Guallar E. Serum ferritin level and risk of the metabolic syndrome in U.S. adults. Diabetes Care. 2004;27:2422–8.
    Article PubMed Google Scholar
  30. Chitturi S, Abeygunasekera S, Farrell GC, Holmes-Walker J, Hui JM, Fung C, et al. NASH and insulin resistance: insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology. 2002;35:373–9.
    Article CAS PubMed Google Scholar
  31. Pagano G, Pacini G, Musso G, Gambino R, Mecca F, Depetris N, et al. Nonalcoholic steatohepatitis, insulin resistance, and metabolic syndrome: further evidence for an etiologic association. Hepatology. 2002;35:367–72.
    Article CAS PubMed Google Scholar
  32. Marcheisini G, Bugianesi E, Forlani G, Cerrelli F, Lenzi M, Manini R, et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology. 2003;37:917–23.
    Article Google Scholar
  33. Ono M, Saibara T. Clinical features of nonalcoholic steatohepatitis in Japan: evidence from literature. J Gastroenterol. 2006;41:725–32.
    Article PubMed Google Scholar
  34. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412–9.
    Article CAS PubMed Google Scholar
  35. Boza C, Riquelme A, Ibañez L, Duarte I, Norero E, Viviani P, et al. Predictors of non-alcoholic steatohepatitis (NASH) in obese patients undergoing gastric bypass. Obes Surg. 2005;15:1148–53.
    Article PubMed Google Scholar
  36. Murawaki Y, Ikuta K, Koda M, Kawasaki H. Serum type III procollagen peptide, type IV collagen 7S domain, central triple-helix of type IV collagen and tissue inhibitor of metalloproteinases in patients with chronic viral liver disease: relationship to liver histology. Hepatology. 1994;20:780–7.
    Article CAS PubMed Google Scholar
  37. Sakugawa H, Nakayoshi T, Kobashigawa K, Yamashiro T, Maeshiro T, Miyagi S, et al. Clinical usefulness of biochemical markers of liver fibrosis in patients with nonalcoholic fatty liver disease. World J Gastroenterol. 2005;11:255–9.
    CAS PubMed Google Scholar
  38. Yoneda M, Mawatari H, Fujita K, Yonemitsu K, Kato S, Takahashi H, et al. Type IV collagen 7s domain is an independent clinical marker of the severity of fibrosis in patients with nonalcoholic steatohepatitis before the cirrhotic stage. J Gastroenterol. 2007;42:375–81.
    Article CAS PubMed Google Scholar
  39. Shimada M, Kawahara H, Ozaki K, Fukura M, Yano H, Tsuchishima M, et al. Usefulness of a combined evaluation of the serum adiponectin level, HOMA-IR, type IV collagen 7S level to predict the early stage of nonalcoholic steatohepatitis. Am J Gastroenterol. 2007;102:1931–8.
    Article CAS PubMed Google Scholar
  40. Kaneda H, Hashimoto E, Yatsuji S, Tokushige K, Shiratori K. Hyaluronic acid levels can predict severe fibrosis and platelet counts can predict cirrhosis in patients with nonalcoholic fatty liver disease. J Gastroenterol Hepatol. 2006;21:1459–65.
    CAS PubMed Google Scholar
  41. Suzuki A, Angulo P, Lymp J, Li D, Satomura S, Lindor K. Hyaluronic acid, an accurate serum marker for severe fibrosis in patients with non-alcoholic fatty liver disease. Liver Int. 2005;25:779–86.
    Article CAS PubMed Google Scholar
  42. Wong VW, Wong GL, Chim AM, Tse AM, Tsang SW, Hui AY, et al. Validation of the NAFLD fibrosis score in a Chinese population with low prevalence of advanced fibrosis. Am J Gastroenterol. 2008;103:1682–8.
    Article PubMed Google Scholar
  43. Fujii H, Enomoto M, Fukushima W, Tamori A, Sakaguchi H, Kawada N. Applicability of BARD score to Japanese patients with NAFLD. Gut. 2009;58:1566–7.
    Article CAS PubMed Google Scholar

Download references

Acknowledgments

The authors thank the following individuals for assistance in preparation of this manuscript: Atsushi Nakajima, M.D., Ph.D., Division of Gastroenterology, Yokohama City University Graduate School of Medicine; Kyoko Sakai, M.D., Yutaka Inada, M.D., Akitoshi Douhara, M.D., Tasuku Hara, M.D., Center for Digestive and Liver Diseases, Nara City Hospital; Tomokazu Ishitobi, M.D., Department of Medicine and Molecular Science, Graduate School of Biomedical Sciences, Hiroshima University; Yoshihiro Kamada, M.D., Ph.D., Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine; Takaaki Ohtake, M.D., Ph.D., Division of Gastroenterology and Hematology/Oncology, Department of Medicine, Asahikawa; Yoshito Itoh, M.D., Ph.D., Toshikazu Yoshikawa, M.D., Ph.D., Department of Gastroenterology and Hepatology, Kyoto Prefectural University of Medicine.

Conflicts of interest

The authors have no conflicts of interest to disclose.

Author information

Authors and Affiliations

  1. Center for Digestive and Liver Diseases, Nara City Hospital, Higashi Kidera-cho 1-50-1, Nara, 630-8305, Japan
    Yoshio Sumida & Kazuyuki Kanemasa
  2. Division of Gastroenterology, Yokohama City University Graduate School of Medicine, Yokohama, Japan
    Masato Yoneda & Koji Fujita
  3. Department of Medicine and Molecular Science, Graduate School of Biomedical Sciences, Hiroshima University, Hiroshima, Japan
    Hideyuki Hyogo & Kazuaki Chayama
  4. Department of Gastroenterology and Hepatology, Kyoto Prefectural University of Medicine, Kyoto, Japan
    Kanji Yamaguchi & Kohichiroh Yasui
  5. Department of Gastroenterology and Hepatology, Kochi Medical School, Kochi, Japan
    Masafumi Ono & Toshiji Saibara
  6. Department of Hepatology, Graduate School of Medicine, Osaka City University, Osaka, Japan
    Hideki Fujii & Norifumi Kawada
  7. Department of Internal Medicine, Saga Medical School, Saga University, Saga, Japan
    Yuichiro Eguchi & Kazuma Fujimoto
  8. Division of Gastroenterology and Hematology/Oncology, Department of Medicine, Asahikawa Medical College, Asahikawa, Japan
    Yasuaki Suzuki & Yutaka Kohgo
  9. Department of Pathology, Nara City Hospital, Nara, Japan
    Shunsuke Imai
  10. Hepatology Center, Saiseikai Suita Hospital, Osaka, Japan
    Takeshi Okanoue

Authors

  1. Yoshio Sumida
  2. Masato Yoneda
  3. Hideyuki Hyogo
  4. Kanji Yamaguchi
  5. Masafumi Ono
  6. Hideki Fujii
  7. Yuichiro Eguchi
  8. Yasuaki Suzuki
  9. Shunsuke Imai
  10. Kazuyuki Kanemasa
  11. Koji Fujita
  12. Kazuaki Chayama
  13. Kohichiroh Yasui
  14. Toshiji Saibara
  15. Norifumi Kawada
  16. Kazuma Fujimoto
  17. Yutaka Kohgo
  18. Takeshi Okanoue

Consortia

Japan Study Group of Nonalcoholic Fatty Liver Disease (JSG-NAFLD)

Corresponding author

Correspondence toYoshio Sumida.

Additional information

All authors are members of the Japan Study Group of NAFLD (JSG-NAFLD).

Rights and permissions

About this article

Cite this article

Sumida, Y., Yoneda, M., Hyogo, H. et al. A simple clinical scoring system using ferritin, fasting insulin, and type IV collagen 7S for predicting steatohepatitis in nonalcoholic fatty liver disease.J Gastroenterol 46, 257–268 (2011). https://doi.org/10.1007/s00535-010-0305-6

Download citation

Keywords